INLEXZO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INLEXZO (INLEXZO).
INLEXZO (sodium phenylbutyrate/taurursodiol) is a combination of two compounds: sodium phenylbutyrate, a histone deacetylase inhibitor that reduces ER stress and apoptosis, and taurursodiol, a bile acid that improves mitochondrial function and reduces oxidative stress. Together, they aim to reduce neuronal cell death in neurodegenerative diseases.
| Metabolism | Sodium phenylbutyrate is metabolized via beta-oxidation and conjugation; taurursodiol undergoes conjugation with taurine and is excreted in bile. CYP450 enzymes are not significantly involved. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 60-70% of the dose) via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for less than 10% of the administered dose. |
| Half-life | Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment. |
| Protein binding | Approximately 90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.6 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 50-60% due to first-pass metabolism; absolute bioavailability may vary with formulation. |
| Onset of Action | Oral: 1-2 hours; Intravenous: within minutes. |
| Duration of Action | Duration of action is 6-12 hours depending on dose and renal function; monitoring of clinical response recommended for dose titration. |
| Molecular Weight | 545.62 |
400 mg orally once daily with food.
| Dosage form | SYSTEM |
| Renal impairment | For GFR 30-89 mL/min: 400 mg once daily. GFR 15-29 mL/min: 200 mg once daily. GFR <15 mL/min or hemodialysis: 200 mg three times per week after dialysis. |
| Liver impairment | Child-Pugh A: 400 mg once daily. Child-Pugh B: 200 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | For patients 12-17 years weighing ≥40 kg: 400 mg once daily. For younger children or weight <40 kg: not established. |
| Geriatric use | No specific dose adjustment required; monitor renal function and use lowest effective dose due to age-related decline. |
| 1st trimester | Limited human data; avoid in first trimester unless benefit outweighs risk. |
| 2nd trimester | No evidence of teratogenicity in animal studies; use cautiously. |
| 3rd trimester | Risk of neonatal complications; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for INLEXZO (INLEXZO).
| Placental transfer | Crosses placenta in rats; human data not available. |
| Breastfeeding | Not recommended during breastfeeding due to potential adverse effects in the infant. |
| Lactation Rating | L4 (Possibly Hazardous) |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to INLEXZO or any excipient
| Precautions | Monitor for sodium overload due to sodium phenylbutyrate content (each packet contains ~1.6 g sodium), Risk of diarrhea (common), may require dose reduction or discontinuation, Hepatic impairment: caution in severe hepatic disease |
| Food/Dietary | No significant food interactions reported. There are no dietary restrictions associated with INLEXZO use. |
| Clinical Pearls | INLEXZO (eflornithine) is an irreversible inhibitor of ornithine decarboxylase, used for reducing facial hirsutism in women. Apply a thin layer to affected areas twice daily; clinical benefit may take 4-8 weeks. Do not use on irritated or broken skin. Avoid concomitant use with other topical depilatories or waxing to minimize irritation. Monitor for skin rash, acne, or pseudofolliculitis barbae. Discontinue if severe hypersensitivity occurs. |
Loading safety data…
| Teratogenic Risk | Insufficient human data; animal studies have not been conducted. Risk cannot be excluded. First trimester: potential for major malformations. Second and third trimesters: potential for fetal toxicity and alterations in fetal growth. Use only if maternal benefit outweighs potential fetal risk. |
| Fetal Monitoring | Monitor maternal renal function, liver function, and complete blood count regularly. Fetal monitoring with ultrasound to assess growth and amniotic fluid volume. Consider non-stress testing or biophysical profile in third trimester if indicated. |
| Fertility Effects | No specific studies on fertility. Based on mechanism, potential for impairment of male and female fertility due to effects on rapidly dividing cells. Preclinical data suggest possible ovarian and testicular toxicity. |
| Patient Advice | Apply a thin layer of cream to the affected facial areas twice daily, at least 8 hours apart. · Do not wash the treated area for at least 4 hours after application. · Use sunscreen and avoid sun exposure, as the skin may become more sensitive. · Results may not be noticeable for 4-8 weeks; continue use as directed. · Avoid using other hair removal methods (e.g., shaving, waxing, plucking) on treated areas unless advised by your doctor. · Inform your doctor if you develop skin rash, redness, stinging, or other signs of irritation. · Do not use on open wounds, sunburned, or irritated skin. |